EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RNAactDrug 2.0: an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets

Feng Li iD, Liying Pei, Jiangtao Xing, Anhui Kang, Zhe Chen, Wensong Liu, Siyao Lu, Longqi Xu, Xinyi Wang, Chunlong Zhang, Yanjun Xu iD

Nucleic Acids Research · 02.11.2026

DOI: 10.1093/nar/gkag1117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 02.11.2026. Verfasst von Feng Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Bioinformatics Science and Technology, Harbin Medical University, 157 Baojian Road, Harbin 150081, China. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Heilongjiang Chunyan Youth Science and Technology Talent team.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNAactDrug 2.0 (available at https://bio-bigdata.hrbmu.edu.cn/RNAactDrug or https://bio-datamining.hrbmu.edu.cn/RNAactDrug) is an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets. We have updated the RNAactDrug 2.0 database with significantly expanded data and improved features, including (i) ∼30 000 drugs, 38 908 RNA molecules, and 22 800 375 drug–RNA associations from large-scale pharmacogenomic databases, covering four molecular layers: expression, copy number variation (CNV), mutation, and methylation; (ii) 11 099 cases from The Cancer Genome Atlas across 33 cancer types are integrated to support clinical and pan-cancer analyses of drug sensitivity-associated RNA features; (iii) ∼3.8 million cells from >200 single-cell RNA sequencing datasets, spanning 34 cancer types and 38 tissues, enable analysis of cell type-specific patterns and intratumoral heterogeneity; (iv) 26 440 enhancers and 788 444 drug-enhancer associations, combined with potential target prediction, provide an exploratory epigenetic regulatory dimension; (v) enhanced search and browsing functionalities, together with seven tools for functional annotation, pan-cancer analysis, tumor microenvironment profiling, single-cell trajectory and CNV analysis, and enhancer-related analyses. In summary, RNAactDrug 2.0 is a crucial resource for the multi-omics dissection of drug sensitivity-associated molecules, providing important support for the discovery of drug resistance biomarkers and the advancement of personalized therapeutic strategies.

Autor:innen und Institutionen

  • College of Bioinformatics Science and Technology, Harbin Medical University, 157 Baojian Road, Harbin 150081, China.

ORCID-Profile: Feng Li, Yanjun Xu

Förderung

  • National Natural Science Foundation of China
  • Heilongjiang Chunyan Youth Science and Technology Talent team

Zitieren

APA

Li, F., Pei, L., Xing, J., Kang, A., Chen, Z., Liu, W., Lu, S., Xu, L., Wang, X., Zhang, C., & Xu, Y. (2026). RNAactDrug 2.0: an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag1117

Vancouver

Li F, Pei L, Xing J, Kang A, Chen Z, Liu W, et al. RNAactDrug 2.0: an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag1117

BibTeX
@article{Li2026,
  author = {Li, Feng and Pei, Liying and Xing, Jiangtao and Kang, Anhui and Chen, Zhe and Liu, Wensong and Lu, Siyao and Xu, Longqi and Wang, Xinyi and Zhang, Chunlong and Xu, Yanjun},
  title = {RNAactDrug 2.0: an updated resource for systematically exploring molecular features associated with drug sensitivity across multi-omics datasets},
  journal = {Nucleic Acids Research},
  year = {2026},
  doi = {10.1093/nar/gkag1117}
}
Kostenlos starten →